Novavax, Inc. (NVAX)
$3.94
-0.09 (-2.23%)
| CAPS Rating |
|
|---|---|
| Open | $3.96 |
| Previous Close | $4.03 |
| Daily Range | $3.85 - $4.03 |
| 52-Week Range | $0.52 - $7.79 |
| Market Cap | $357.81M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 1,635,738 |
| Average Daily Volume | 4,489,000 |
NVAX
VS S&P 500 (SPY)
How do you think NVAX will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
NVAX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
NVAX News and Commentary
- Novavax begins H1N1 flu vaccine study in Mexico, shares rise – Reuters
- 5 Stocks Bucking the Downtrend – The Motley Fool
- 5 Stocks Springing Back – The Motley Fool
- Great Call on Alcoa! What's Next? – The Motley Fool
- You’d Be Stupid to Buy These Stocks – The Motley Fool
- Tuesday's Biggest Stock Stars – The Motley Fool
- Fearful Stocks for Greedy Investors – The Motley Fool
- China says to order 100M doses of H1N1 vaccine by 2nd Phase. – Blog at The Motley Fool
- 3 Stocks in a Tailspin – The Motley Fool
- Keep in mind flu shot will not protect you against H1N1 – Blog at The Motley Fool
- Rocket Stock or Dud? – The Motley Fool
- Wednesday's Biggest Stock Stars – The Motley Fool
- Bio-rhythms. – Blog at The Motley Fool
- Novavax shares fall on plans to sell stock – Reuters
- Battle brewing between two biotechs NVAX & SVA – Blog at The Motley Fool
- Sirius (SIRI) to HOT to handle? And other thoughts (LTS, NVAX) – Blog at The Motley Fool
- Wall Street's Buy List – The Motley Fool
- H1N1 R&D Biotechs, More Virulent Than The Flu Strain Itself? – Blog at The Motley Fool
- 3 Stocks Hitting High Notes – The Motley Fool
- 5 Cold Stocks Heating Up – The Motley Fool
RSS Headlines
Fool UK
